News - MedTech & Diagnostics
GE HealthCare forges ahead in medtech innovation and precision health post business separation

MedTech & Diagnostics News: In an interview with Health Industry Hub, Amit Yadav, CEO of GE HealthCare ANZ spotlighted GE Healthcare’s collaboration with Queensland Health for a first-of-its-kind cardiology solution aimed at enhancing efficiency and access to optimal care.
He delved into insights from GE HealthCare’s recent survey of stakeholders revealing that clinicians trust AI for supporting clinical decision-making, while patients express hesitance toward care outside the traditional clinical settings despite the changing landscape driven by hospitals and private insurers.
Addressing the evolving role of digital health, Yadav highlighted AI’s importance in early disease detection, remote monitoring, and the company’s focus on predictive AI that is enhancing patient and family experiences.
Lastly, Yadav expressed excitement about GE Healthcare’s future following the company’s separation of its healthcare business, saying “The separation really solidified the company’s focus and commitment to the future of healthcare innovation. We’re enabling precision health, personalising healthcare technologies and integrating efficiencies into the health system.
“As a standalone company, we’re better positioned to invest in both organic and inorganic areas to drive growth faster in healthcare.”
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More